PL3421051T3 - Sposoby glikokoniugacji i kompozycje - Google Patents
Sposoby glikokoniugacji i kompozycjeInfo
- Publication number
- PL3421051T3 PL3421051T3 PL18183661T PL18183661T PL3421051T3 PL 3421051 T3 PL3421051 T3 PL 3421051T3 PL 18183661 T PL18183661 T PL 18183661T PL 18183661 T PL18183661 T PL 18183661T PL 3421051 T3 PL3421051 T3 PL 3421051T3
- Authority
- PL
- Poland
- Prior art keywords
- glycoconjugation
- compositions
- processes
- glycoconjugation processes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684043P | 2012-08-16 | 2012-08-16 | |
| PCT/IB2013/056597 WO2014027302A1 (en) | 2012-08-16 | 2013-08-12 | Glycoconjugation processes and compositions |
| EP13779365.9A EP2885007B1 (en) | 2012-08-16 | 2013-08-12 | Glycoconjugation processes and compositions |
| EP18183661.0A EP3421051B1 (en) | 2012-08-16 | 2013-08-12 | Glycoconjugation processes and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3421051T3 true PL3421051T3 (pl) | 2020-10-05 |
Family
ID=49385307
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18183661T PL3421051T3 (pl) | 2012-08-16 | 2013-08-12 | Sposoby glikokoniugacji i kompozycje |
| PL13779365T PL2885007T3 (pl) | 2012-08-16 | 2013-08-12 | Sposoby glikokoniugacji i kompozycje |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13779365T PL2885007T3 (pl) | 2012-08-16 | 2013-08-12 | Sposoby glikokoniugacji i kompozycje |
Country Status (32)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE049531T2 (hu) | 2012-08-16 | 2020-10-28 | Pfizer | Glikokonjugációs eljárások és kompozíciók |
| CA3170344C (en) | 2014-01-21 | 2023-08-29 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| ES2965616T3 (es) * | 2014-01-21 | 2024-04-16 | Pfizer | Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos |
| JP6612260B2 (ja) | 2014-01-21 | 2019-11-27 | ファイザー・インク | 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート |
| EP3104886B1 (en) | 2014-02-14 | 2018-10-17 | Pfizer Inc | Immunogenic glycoprotein conjugates |
| US9994605B2 (en) | 2014-03-13 | 2018-06-12 | Universitaet Basel | Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein |
| IL252915B2 (en) | 2015-01-15 | 2024-04-01 | Pfizer | Immunogenic compositions for use in pneumococcal vaccines |
| MX368897B (es) * | 2015-05-04 | 2019-10-21 | Pfizer | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos. |
| KR102690378B1 (ko) * | 2015-06-08 | 2024-08-01 | 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 | 다당류-단백질 접합체의 흡착을 개선시키는 방법 및 그로부터 수득된 다가 백신 제제 |
| TWI720448B (zh) | 2015-07-21 | 2021-03-01 | 美商輝瑞股份有限公司 | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 |
| CA2996073A1 (en) * | 2015-09-16 | 2017-03-23 | Universitat Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| CA3005524C (en) | 2015-11-20 | 2023-10-10 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US11224652B2 (en) | 2016-08-05 | 2022-01-18 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| MY199856A (en) | 2016-08-05 | 2023-11-25 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| DK3506935T3 (en) | 2016-09-02 | 2024-04-02 | Sanofi Pasteur Inc | Neisseria meningitidis-vaccine |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| IL317054A (en) | 2016-12-30 | 2025-01-01 | Vaxcyte Inc | Polypeptide-antigen conjugates with unnatural amino acids |
| KR102459629B1 (ko) | 2017-01-20 | 2022-10-28 | 화이자 인코포레이티드 | 폐렴구균 백신에 사용하기 위한 면역원성 조성물 |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| CA3066911C (en) * | 2017-06-10 | 2022-05-24 | Inventprise, Llc | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
| BR112020004396A8 (pt) | 2017-09-07 | 2023-01-31 | Merck Sharp & Dohme | Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora |
| CN111050794B (zh) | 2017-09-07 | 2025-03-11 | 默沙东有限责任公司 | 将肺炎球菌多糖与载体蛋白缀合的配制方法 |
| SG11202006388SA (en) | 2018-02-05 | 2020-07-29 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| SG11202006387QA (en) | 2018-02-05 | 2020-07-29 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| MX2020009825A (es) * | 2018-03-23 | 2020-12-11 | Koranex Capital | Glicoconjugados de precision como herramientas terapeuticas. |
| EP3782642A4 (en) | 2018-04-18 | 2022-04-13 | SK Bioscience Co., Ltd. | CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CN111024832B (zh) * | 2019-10-29 | 2022-05-03 | 北京成大天和生物科技有限公司 | 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法 |
| KR20220092572A (ko) | 2019-11-01 | 2022-07-01 | 화이자 인코포레이티드 | 에스케리키아 콜라이 조성물 및 그 방법 |
| KR20220144393A (ko) | 2020-02-21 | 2022-10-26 | 화이자 인코포레이티드 | 당류의 정제 |
| JP2023514697A (ja) | 2020-02-23 | 2023-04-07 | ファイザー・インク | 大腸菌組成物およびその方法 |
| WO2022035816A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| IL301248B2 (en) | 2020-09-17 | 2024-04-01 | Janssen Pharmaceuticals Inc | Multivalent vaccine compositions and uses thereof |
| JP2023546446A (ja) | 2020-10-22 | 2023-11-02 | ファイザー・インク | 細菌多糖を精製する方法 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| TW202227467A (zh) | 2020-10-27 | 2022-07-16 | 美商輝瑞大藥廠 | 大腸桿菌組合物及其方法 |
| CN116744965A (zh) | 2020-11-04 | 2023-09-12 | 辉瑞大药厂 | 用于肺炎球菌疫苗的免疫原性组合物 |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| EP4333879A1 (en) | 2021-05-03 | 2024-03-13 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| MX2023013434A (es) | 2021-05-28 | 2023-12-12 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos. |
| US20220387576A1 (en) | 2021-05-28 | 2022-12-08 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| IL321062A (en) | 2022-11-22 | 2025-07-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP4626405A1 (en) | 2022-12-01 | 2025-10-08 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2024255922A1 (en) | 2023-04-14 | 2025-10-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121263203A (zh) | 2023-05-19 | 2026-01-02 | 葛兰素史克生物有限公司 | 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法 |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US578573A (en) | 1897-03-09 | Brake-actuating mechanism | ||
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| JPH07507854A (ja) | 1991-12-23 | 1995-08-31 | ツォッヒェ，ミヒャエル | 油除去装置を備えたエンジン |
| DK0616034T3 (da) | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid til fremstilling af CRM-protein og diphtheria toxin |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| CA2293739A1 (en) | 1997-06-12 | 1998-12-17 | Shin-Etsu Bio, Inc. | Production of non-native bacterial exopolysaccharide in a recombinant bacterial host |
| KR100659803B1 (ko) | 1998-09-30 | 2006-12-19 | 와이어쓰 홀딩스 코포레이션 | 보조제로서 돌연변이체 콜레라 홀로톡신 |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
| EP1355673B1 (en) * | 2001-01-23 | 2012-05-30 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| IL159210A0 (en) | 2001-06-07 | 2004-06-01 | Wyeth Corp | Mutant forms of cholera holotoxin as an adjuvant |
| MXPA03011135A (es) | 2001-06-07 | 2004-09-08 | Wyeth Corp | Formas mutantes de holotoxina de colera como adyuvante. |
| CN1394867A (zh) * | 2001-07-06 | 2003-02-05 | 中国科学院生态环境研究中心 | 可作药物的寡糖和其制备方法及含该寡糖的药物组合物 |
| WO2004031394A2 (en) * | 2002-10-03 | 2004-04-15 | Wyeth Holdings Corporation | Process for preparing monoprotected diols from symmetric diols |
| CA2517439C (en) | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| CA2519511A1 (en) | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| DK1735321T3 (da) * | 2004-04-14 | 2009-01-12 | Wyeth Corp | Fremgangsmåde til fremstilling af rapamycin 42-estere og FK-506 32-estere med dicarboxylsyre, precursors for rapamycinkonjugater og antistoffer |
| US7910753B2 (en) * | 2004-09-10 | 2011-03-22 | Anaspec Incorporated | Cyanine dyes and their applications as luminescence quenching compounds |
| SI1868645T1 (sl) | 2005-04-08 | 2012-04-30 | Wyeth Llc | Večvalentni pnevmokokni sestavek konjugata polisaharid-protein |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| AR058592A1 (es) * | 2005-12-22 | 2008-02-13 | Glaxosmithkline Biolog Sa | Vacuna |
| TW200806685A (en) * | 2006-02-21 | 2008-02-01 | Wyeth Corp | Processes for the convergent synthesis of calicheamicin derivatives |
| TW200812622A (en) * | 2006-03-07 | 2008-03-16 | Wyeth Corp | Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
| US20070253985A1 (en) | 2006-04-26 | 2007-11-01 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| DE102006026436A1 (de) * | 2006-06-07 | 2007-12-13 | Continental Aktiengesellschaft | Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche |
| CN105267974A (zh) * | 2007-06-20 | 2016-01-27 | 辉瑞爱尔兰制药公司 | 用于缀合疫苗的经过修饰的多糖 |
| RU2378015C2 (ru) * | 2008-04-02 | 2010-01-10 | Равшан Иноятович Атауллаханов | Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности |
| EP3461496B1 (en) * | 2009-06-22 | 2023-08-23 | Wyeth LLC | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| ES2576853T3 (es) * | 2009-07-03 | 2016-07-11 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Compuestos dirigidos al receptor del manosa 6-fosfato independiente de cationes |
| CN102762196B (zh) * | 2009-11-24 | 2014-05-14 | 基立福疗法公司 | 冻干方法、组合物和试剂盒 |
| KR20140005892A (ko) * | 2010-12-10 | 2014-01-15 | 머크 샤프 앤드 돔 코포레이션 | 면역원성 조성물의 진탕-유도된 응집을 완화시키는 신규한 제제 |
| KR102109067B1 (ko) * | 2011-09-07 | 2020-05-13 | 프로린크스 엘엘시 | 생분해성 교차결합을 가지는 하이드로젤 |
| HUE049531T2 (hu) | 2012-08-16 | 2020-10-28 | Pfizer | Glikokonjugációs eljárások és kompozíciók |
| CA3170344C (en) | 2014-01-21 | 2023-08-29 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP3104886B1 (en) | 2014-02-14 | 2018-10-17 | Pfizer Inc | Immunogenic glycoprotein conjugates |
-
2013
- 2013-08-12 HU HUE18183661A patent/HUE049531T2/hu unknown
- 2013-08-12 NZ NZ704490A patent/NZ704490A/en unknown
- 2013-08-12 JP JP2015527054A patent/JP6291495B2/ja active Active
- 2013-08-12 PT PT13779365T patent/PT2885007T/pt unknown
- 2013-08-12 SI SI201331739T patent/SI3421051T1/sl unknown
- 2013-08-12 PT PT181836610T patent/PT3421051T/pt unknown
- 2013-08-12 RU RU2015103017A patent/RU2645071C2/ru active
- 2013-08-12 CN CN201380049088.XA patent/CN104661684B/zh active Active
- 2013-08-12 HU HUE13779365A patent/HUE041381T2/hu unknown
- 2013-08-12 PE PE2015000211A patent/PE20150464A1/es active IP Right Grant
- 2013-08-12 MX MX2015001992A patent/MX363511B/es unknown
- 2013-08-12 ES ES13779365T patent/ES2700824T3/es active Active
- 2013-08-12 WO PCT/IB2013/056597 patent/WO2014027302A1/en not_active Ceased
- 2013-08-12 DK DK13779365.9T patent/DK2885007T3/en active
- 2013-08-12 RU RU2016136630A patent/RU2724840C2/ru active
- 2013-08-12 US US14/420,822 patent/US9517274B2/en active Active
- 2013-08-12 KR KR1020157006296A patent/KR101742406B1/ko active Active
- 2013-08-12 AU AU2013303826A patent/AU2013303826B2/en active Active
- 2013-08-12 SI SI201331242T patent/SI2885007T1/sl unknown
- 2013-08-12 PL PL18183661T patent/PL3421051T3/pl unknown
- 2013-08-12 EP EP13779365.9A patent/EP2885007B1/en active Active
- 2013-08-12 ES ES18183661T patent/ES2800479T3/es active Active
- 2013-08-12 BR BR112015003227-3A patent/BR112015003227B1/pt active IP Right Grant
- 2013-08-12 PL PL13779365T patent/PL2885007T3/pl unknown
- 2013-08-12 SG SG11201500566XA patent/SG11201500566XA/en unknown
- 2013-08-12 MY MYPI2015700444A patent/MY167579A/en unknown
- 2013-08-12 CA CA2881420A patent/CA2881420C/en active Active
- 2013-08-12 EP EP18183661.0A patent/EP3421051B1/en active Active
- 2013-08-12 IN IN694DEN2015 patent/IN2015DN00694A/en unknown
- 2013-08-12 DK DK18183661.0T patent/DK3421051T3/da active
- 2013-08-15 AR ARP130102904A patent/AR092368A1/es active IP Right Grant
- 2013-08-15 TW TW102129348A patent/TWI480049B/zh active
-
2015
- 2015-02-02 IL IL237066A patent/IL237066B/en active IP Right Grant
- 2015-02-04 PH PH12015500243A patent/PH12015500243B1/en unknown
- 2015-02-15 SA SA515360035A patent/SA515360035B1/ar unknown
-
2016
- 2016-11-09 US US15/347,034 patent/US9950054B2/en active Active
-
2018
- 2018-04-05 US US15/946,664 patent/US10583187B2/en active Active
-
2020
- 2020-01-28 US US16/774,309 patent/US11110160B2/en active Active
-
2021
- 2021-08-05 US US17/395,108 patent/US11723965B2/en active Active
-
2022
- 2022-07-22 LU LU00273C patent/LUC00273I2/fr unknown
- 2022-07-25 NL NL301188C patent/NL301188I2/nl unknown
- 2022-07-28 HU HUS2200034C patent/HUS2200034I1/hu unknown
- 2022-07-28 FR FR22C1037C patent/FR22C1037I2/fr active Active
- 2022-08-04 NO NO2022034C patent/NO2022034I1/no unknown
- 2022-08-05 FI FIC20220032C patent/FIC20220032I1/fi unknown
-
2023
- 2023-06-21 US US18/338,961 patent/US12447203B2/en active Active
-
2024
- 2024-10-28 AR ARP240102937A patent/AR134188A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237066B (en) | Glycoconjugation processes and preparations | |
| ZA201408594B (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
| GB2506426B (en) | Composition | |
| GB201200707D0 (en) | Composition | |
| GB201218954D0 (en) | Composition | |
| GB2498803B (en) | Composition | |
| GB201315350D0 (en) | Methods and compositions | |
| GB2508825B (en) | Composition | |
| EP2874641A4 (en) | COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF | |
| GB201315347D0 (en) | Methods and compositions | |
| HRP20190326T1 (hr) | Pripravak | |
| GB201206035D0 (en) | Composition | |
| IL236357A0 (en) | The composition of misoprostol | |
| EP2910537A4 (en) | AGENT COMPOSITION GENERATING GAS | |
| GB201218195D0 (en) | Composition | |
| GB201209597D0 (en) | Composition | |
| GB201208133D0 (en) | Composition | |
| GB201311517D0 (en) | Composition | |
| GB201219383D0 (en) | Composition | |
| SMT201700322T1 (it) | Composizione dermoprotettiva e dermoequilibrante | |
| ZA201500493B (en) | Glycoconjugation processes and compositions | |
| GB201223224D0 (en) | Composition | |
| GB201221334D0 (en) | Composition | |
| GB201220838D0 (en) | Composition | |
| GB201219065D0 (en) | Composition |